Skip to main content
. 2014 Mar 27;7:27. doi: 10.1186/1756-8722-7-27

Figure 4.

Figure 4

Time course of hematological parameters of patient 4 in relation to eculizumab treatment and SSAE treatment. Eculizumab was started in December 2007. SSAE of the three main branches of the splenic artery was performed in June, July, and November 2008. It is seen that the rather severe thrombocytopenia did not respond to eculizumab (nor was that expected), but it did respond to SSAE; the transfusion requirement decreased somewhat on eculizumab but much more after SSAE.